HATFIELD, England, March 11, 2015 /PRNewswire/ --
PRESS STATEMENT FOR UK MEDIA
Cancer Programme of Care Board upholds the appeals against original decisions from the National Cancer Drugs Fund in England
Eisai today announces that Halaven® (eribulin) will remain on the National Cancer Drugs Fund (NCDF) pending reconsideration by the NCDF panel. The reconsideration is the result of the appeals submitted by Eisai following the original decision by NHS England to remove eribulin from the NCDF. Eribulin will remain available to patients pending the result of the reconsideration.
Eribulin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
Eribulin remains the only single agent chemotherapy to significantly improve overall survival in women with advanced breast cancer after anthracycline and taxane treatment. To date, eribulin is the sixth most prescribed treatment in the NCDF and has been used by more than 2,000 women in England since 2011.
1. SmPC Halaven (updated June 2014). Available at:http://www.medicines.org.uk/emc/medicine/24382/spc/halaven+0.44+mg+ml+solution+for+injection: Accessed March 2015
2. Cortes J et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study: The Lancet. 2011;377: 914-923
Job code: Halaven-UK0408
Date of preparation: March 2015
SOURCE Eisai Europe Limited